INCY Incyte Corporation

87.61
+0.69  (+1%)
Previous Close 86.92
Open 87.25
Price To Book 9
Market Cap 18,786,961,278
Shares 214,438,549
Volume 1,231,090
Short Ratio
Av. Daily Volume 1,377,650

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met primary endpoint - February 4, 2019. Data to be presented 2019.
Baricitinib
Atopic dermatitis
NDA filing to be submitted 2H 2019.
INCB54828 (FIGHT-202)
Cholangiocarcinoma
Phase 2 interim data released at ASH 2018.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2 enrolment to be completed in 2019.
INCB54828 (FIGHT-201)
Bladder cancer
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 data due 2H 2019.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 2 trial to be discontinued - noted June 21, 2018.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal Phase 2 trial initiation announced November 15, 2017.
Ruxolitinib (RESET-272)
Essential thrombocythemia
Phase 3 data due by the end of 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
FDA approval announced May 24, 2019.
Ruxolitinib
Graft versus host disease
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3 trial to commence 1H 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
INC280
Non-small cell lung cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1/2 ongoing.
INCB024360 + Epacadostat
Solid tumors
Phase 3 data due 2020.
Ruxolitinib
Atopic dermatitis
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 1 data due 2021.
INCMGA0012
Anal cancer
Phase 1 poster presentation at AACR April 1, 2019.
INCMGA0012
Solid tumors
Phase 1 data due 2020.
INCMGA0012
Endometrial cancer
Phase 1/2 initial data due 2019.
INCB53914 and ruxolitinib
Myelofibrosis and Solid Tumors
Phase 2 data presented at ASH December 2, 2018.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 2 data presented at WCD meeting June 15, 2019. Primary endpoint met. Phase 3 trial planned for 2H 2019.
Ruxolitinib
Vitiligo
Phase 2 top-line data due 2H 2019.
DPX-Survivac and epacadostat (DeCidE1)
Ovarian cancer
Phase 1/2 data due 2H 2019.
INCB001158
Solid tumors
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 commencement of dosing announced January 22, 2019.
Itacitinib - GRAVITAS-309
Chronic Graft-Versus-Host Disease
Phase 3 initiation of dosing announced June 4, 2019.
Pemigatinib (FIGHT-302)
Cholangiocarcinoma - first line